Abstract
Background:
The pathophysiology of ischemic stroke is not fully elucidated. Upregulation of FKBP5 in brain ischemia/reperfusion injury has been found to be associated with the severity of ischemic and reperfusion damage. However, its specific role in ischemic stroke progression remains unclear.
Methods:
A total of 40 ischemic stroke patients and 40 age- and sex-matched healthy donors (HDs) were enrolled in this work to evaluate the expression of FKBP5, the formation of neutrophil extracellular trap (NET), and the correlation between NET and stroke. Moreover, transient middle cerebral artery occlusion (tMCAO) mouse model with 60 min occlusion (n = 15/group) was treated with CI-amidine to demonstrate the effect of NET on the stroke-related brain injury. Primary neurons were isolated from mouse brain tissue to evaluated the effect of NET on neuronal apoptosis through flow cytometry the TUNEL assays. In addition, BV2 microglial cells were transfected with FKBP5 overexpression and knockdown vectors. The microglial cells polarization, neutrophil NETs formation, and the underlying molecular action mechanism were measured. For specific methods: detected the levels of H3cit, MPO-DNA, IL-1β, IL-10, TNFα, and iNOS by ELISA; Pathological staining was viewed for the neuronal morphological changes; flow cytometry and TUNEL staining were viewed for the neuronal cell apoptosis; detected the protein levels of FKBP5, CD206, CCL5, and MAPK pathway by western blot.
Results:
In this study, we observed significant upregulation of FKBP5 in ischemic stroke patients, which was associated with increased expression of NET markers, such as H3cit and MPO-DNA complexes. This upregulation correlated with stroke severity and outcomes. In a transient middle cerebral artery occlusion (tMCAO) mouse model, treatment with the NET inhibitor CI-amidine significantly reduced brain injury, infarct size, and NET marker levels, suggesting therapeutic potential in targeting NETs. We further found that FKBP5 modulates microglial polarization towards a pro-inflammatory M1 phenotype and promotes NET formation. FKBP5 interacts with CCL5, enhancing MAPK pathway activation and increasing pro-inflammatory cytokine production, including TNF-α and IL-1β. Intervention with the MAPK pathway inhibitor AZD6244 effectively inhibited these effects.
Conclusions:
The current findings suggest that FKBP5 might modulate CCL5-mediate p38 MAPK signaling and NET formation, thereby contributing to post-stroke neuroinflammation and neuronal apoptosis. Further prospective research is needed to verify the potential of FKBP5 as therapeutic targets for ischemic stroke treatment.
Introduction
Stroke is a common and severe condition that poses a significant threat to human health, characterized by high incidence, disability, and mortality rates (). Recent studies have increasingly underscored the critical role of inflammatory responses in the pathophysiology of stroke, particularly ischemic stroke (, ). Understanding the underlying mechanisms of inflammation in ischemic stroke is crucial for developing effective therapeutic strategies.
Recent studies have highlighted a significant role of Neutrophil Extracellular Traps (NETs) in the pathophysiology of ischemic stroke (, ). NETs are web-like structures composed of DNA and various proteins that are released by activated neutrophils. During NET formation, neutrophils release their DNA along with granule proteins. Citrullination of histone H3 by the enzyme peptidyl arginine deiminase 4 (PAD4) is a crucial step in this process, as it is required for chromatin decondensation and DNA release (). NET formation is considered neutrophil-specific and distinct from other cell death pathways, such as apoptosis and necrosis. Consequently, citrullinated histone H3 (H3Cit) has been proposed as a specific biomarker for NET formation (). In addition, Neutrophils produce NETs by expelling decondensed DNA chromatin coated with H3Cit, along with cytoplasmic granule enzymes such as myeloperoxidase (MPO) and neutrophil elastase, into the extracellular space (). The soluble remnants of NETs, primarily cell-free (cf)-DNA, are found in supernatant fluid in vitro and in serum or tissue fluid in vivo ().These structures play crucial roles in both immune response and the progression of neuroinflammation following stroke. NETs promote thrombosis and disrupt the blood-brain barrier, exacerbating neuroinflammatory responses. The disruption of the blood-brain barrier is critical as it allows the infiltration of peripheral immune cells, which further amplifies the inflammatory milieu within the central nervous system (, ).
Microglia, the resident immune cells of the central nervous system, play pivotal roles in mediating inflammatory processes following stroke. These cells can regulate inflammation through various mechanisms, including the release of pro-inflammatory cytokines, phagocytosis of damaged cells, and the modulation of other glial cell functions. The polarization of microglia, particularly toward M1 phenotype, is closely associated with inflammatory damage following stroke (, ). M1 microglia contribute to inflammation through the secretion of various cytokines, whereas M2 microglia play neuroprotective roles in stroke.
FK506 binding protein 5, known as FKBP5, belongs to the immunoaffinity protein family and plays a role in various cellular processes (). As a chaperone protein, FKBP51 regulates the transcription factor nuclear factor kappa B (NF-κB), thereby influencing the expression of proinflammatory cytokines (). Yu et al. found that FKBP5 is significantly upregulated in patients with acute ischemic stroke and the upregulation of FKBP5 in brain ischemia/reperfusion injury is associated with the severity of ischemic and reperfusion damage (). Fang et al. reported that inhibiting the FKBP5-p38 MAPK axis attenuates oxygen-glucose deprivation/reperfusion-induced cardiomyocyte ferroptosis and excessive mitophagy, suggesting its cardioprotective potential against myocardial ischemia/reperfusion injury (). A recent study demonstrated that the absence of FKBP5 decreases cell-crystal adhesion, diminishes apoptosis, enhances cell proliferation, suppresses M1 macrophage polarization and chemotaxis through inhibiting the NF-κB signaling (). Our study observed the upregulation of FKBP5 in patients with ischemic stroke using transcriptome sequencing. However, whether FKBP5 regulates microglial polarization to influence ischemic stroke remains unknown.
Emerging research highlights the association between NETs and microglial activation in various neurological disorders, suggesting that understanding this interplay may yield valuable therapeutic insights (, ). Additionally, cytokines released by activated microglia may further promote NET formation, perpetuating a vicious cycle of inflammation (). The relationship between FKBP5 and neuroinflammatory response also warrants further exploration, as FKBP5 has been implicated in regulating stress responses and immune function ().
Thus, in this work, we hypothesized that FKBP5 might mediate ischemic stroke through regulating NETs and microglia polarization. To demonstrate this hypothesis, we first examined the pathological role of NETs in ischemic stroke through clinical cases and in vivo experiments, followed by in vitro investigations into FKBP5’s effects on NETs and microglial polarization along with the underlying mechanisms involved.
Methods
Ischemic stroke patients and samples
Patients admitted to Liaocheng People’s Hospital from January 2018 to September 2022, and diagnosed as ischemic stroke according to Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018 were enrolled in this study. Inclusion Criteria: (1) Newly confirmed acute cerebral infarction via CT or MRI; (2) Age 50–70 years; (3) Time from symptom onset < 6 hours; (4) Neurological deficits (e.g., speech impairment or limb motor dysfunction) persisting for ≥ 30 minutes; (5) Ability to cooperate with study procedures, with both the patient and legally authorized representative providing signed informed consent after understanding the study; (6) National Institutes of Health Stroke Scale score ≥ 3 and ≤10. Exclusion Criteria: (1) Intracranial hemorrhage (including parenchymal, intraventricular, subarachnoid, or subdural/extradural hemorrhage); (2) History of severe head trauma or stroke within 3 months; (3) Major surgery within 4 weeks or arterial puncture at a non-compressible site within 1 week; (4) Chronic anticoagulant use with INR >1.7 or PT >15 seconds; (5) Abnormal procoagulant indices (e.g., platelet count <90 × 109/L); (6) Severe uncontrolled hypertension, with ineffective pharmacological control; (7) Blood glucose <2.8 mmol/L or >22.2 mmol/L; (8) Radiological evidence of large territory infarction (>1/3 of MCA territory on CT/MRI). For comorbidities, calcium channel blockers or angiotensin-converting enzyme inhibitors were generally selected for hypertension management, while biguanides, insulin secretagogues, or subcutaneous insulin administration were typically employed for glycemic control. Through calculation, a total of 80 samples were gathered, consisting of 40 from ischemic stroke patients and 40 from age- and sex-matched healthy donors (HDs). Cells in the blood samples were eliminated through low-speed centrifugation, and plasma was collected and stored at -80°C. In addition, ten brain tissues from patients with cerebral infarction were collected to validate the expression of FKBP5 detected using transcriptome sequencing previously, and brain tissue obtained from individuals who died in car accidents was used as the control group. The study received approval from the ethics committee of Liaocheng People’s Hospital and adhered to the principles of the Declaration of Helsinki. Informed consent was obtained from all participants, and written consent was specifically obtained from the parents of participants.
H3cit measurement
Plasma samples were diluted (1:2), and the levels of H3cit were measured according to the manufacturer’s instructions using the Citrullinated Histone H3 ELISA Kit (YJ701102, mlbio).
Measurement of MPO-DNA complexes
MPO-DNA complexes were quantified using an ELISA kit (YJ360097, mlbio). Briefly, a 96-well plate was coated overnight with anti-MPO antibody at 4°C, followed by blocking with 2.5% BSA in PBS for 2 hours at room temperature. After washing, the plate was incubated for 90 minutes at room temperature with 20% human or mouse plasma in blocking buffer. Following five washes, the plate was incubated for another 90 minutes at room temperature with anti-DNA antibody. After five additional washes, the plate was developed with ABTS substrate.
Quantification of plasma DNA
Plasma samples were collected from human whole blood by centrifugation at 500×g for 20 minutes. The DNA in plasma was quantified according to the manufacturer’s instructions of the Quant-iT PicoGreen dsDNA Assay kit (12641ES01, Yeasen).
tMCAO model
A transient middle cerebral artery occlusion (tMCAO) stroke model was established as previously reported. Briefly, the right middle cerebral artery (MCA) was occluded by inserting a standardized monofilament (Doccol Corp.) through the right internal carotid artery. The occlusion was maintained for 60 minutes. The occurrence of ischemic stroke was confirmed by neurological tests during the occlusion period. Anesthesia was induced using the inhalation of 5% isoflurane and maintaining with 2% isoflurane. Buprenorphine was administered 1 hour before surgery and every 12 hours as needed. A sham surgery was performed similarly, without the monofilament insertion. Mice were maintained under standard housing conditions with ad libitum access to food and water, and a controlled 12-hour light/12-hour dark photoperiod cycle. Mice were excluded from endpoint analyses based on the following criteria: (a) death within 12 hours after tMCAO; (b) an operation time longer than 10 minutes; (c) the occurrence of surgical complications. Mice brains were visually inspected for surgical complications and stained with 2,3,5-triphenyl tetrazolium chloride (TTC) to confirm the ischemia-related mortality.
Animal experimental design
To elucidate therapeutic effect of CI-amidine, an inhibitor of PAD4 that can inhibit the formation of NETs (), on stroke, a total of 45 male C57BL/6 mice (6–8 weeks old) were randomly divided into three groups (n=15/group): the sham group, tMCAO model group (stroke) and tMCAO+CI-amidine group (stroke+CI). CI-amidine (1373232-26-8, MCE) was dissolved in saline and injected 1 hour after tMCAO induction. The compound was administered once daily at a dose of 50 mg/kg via intraperitoneal injection for three consecutive days. All subjects were euthanized 24 hours after the final administration for subsequent endpoint analyses. The animal study was reviewed and approved by the Ethics Committee for Experimental Animals of Liaocheng People’s Hospital.
Determination of brain water content
Cerebral edema induced by elevated brain water content constitutes a cardinal pathological process that severely compromises prognosis following ischemic stroke (). Thus, we detected the brain water content in the mice to evaluate the condition of stroke (). Mice were decapitated under deep anesthesia 24 hours after tMCAO induction. Brain samples were quickly excised and divided into left and right cerebral hemispheres, cerebellum and brain stem. These four parts were weighed (wet weight), then dried at 55°C for 72 hours and weighed again (dry weight). The BWC percentage was calculated using the formula: water content %= (wet weight−dry weight)/wet weight×100%.
Neurons isolation
Primary neurons were prepared from the brain tissue of 6-8-week-old C57BL/6 mice. Dissociated cortical cells were plated onto poly-D-lysine-coated 6-well plates at a density of 7×10^5 cells per well. After 4 hours of plating, the culture medium was replaced with Neurobasal medium supplemented with B-27. Subsequently, cells were maintained in a humidified incubator at 37°C with 5% CO2.
MACS sorting of microglia
Microglia isolation was performed using CD11b-based MACS sorting. After tissue dissociation, cells were co-stained with Anti-CD11b Magnetic Microbeads (Miltenyi Biotec, CD11b MicroBeads Ultrapure) for 15 minutes on ice under light-protected conditions. Cells were subsequently washed with PBS and centrifuged at 400 ×g for 10 minutes at 4°C. The supernatant was aspirated, and cells were resuspended in sorting buffer. Prior to separation, LS columns were pre-equilibrated with 3 ml PBS and positioned in a magnetic separator. The cell suspension was applied to the column, followed by three washes with 10 ml PBS each. Magnetically labeled cells were eluted by removing the column from the separator and flushing with 5 ml PBS into a 15 ml collection tube. The isolated microglia were pelleted by centrifugation (400 ×g, 10 min) and collected for downstream applications.
Hematoxylin-eosin staining
HE staining was performed to evaluate morphological changes following tMCAO as previous study (). Brain tissues with infarction from each group were collected, fixed in paraformaldehyde, dehydrated, embedded in wax, and sectioned. The sections were subsequently stained with HE as previously reported.
Immunohistochemistry analysis
As previous study (), Paraffin-embedded brain tissue sections from each group were deparaffinized by baking at 60°C for 1 hour, followed by the treatment with xylene and a gradient of ethanol for rehydration. Antigen retrieval was performed using high-pressure treatment with citrate buffer. After quenching endogenous peroxidase and blocking with 5% goat serum, sections were incubated overnight at 4°C with primary antibodies (H3cit, bsm-33042, Bioss; MPO, ab208670, Abcam). Subsequently, goat anti-rabbit secondary antibodies were applied at 37°C for 1 hour. DAB staining was conducted for 5–10 minutes, followed by hematoxylin counterstaining for 20 seconds. Finally, the slides were dehydrated, sealed, and observed under a microscope.
Immunofluorescence staining
Mice brain tissues with infarction were perfused with ice-cold PBS and swiftly extracted. The brains were fixed in 4% paraformaldehyde (PFA) at 4°C for 24 hours. Coronal sections of 8 μm thickness were obtained using a cryostat (Leica, Model CM1950, Germany). The sections were washed with PBS and permeabilized with 0.1% Triton X-100 (Sigma Aldrich) for 30 minutes. After permeabilization, the sections were incubated with 3% BSA at room temperature for 1 hour to block non-specific binding. Subsequently, the sections were incubated overnight at 4°C with following primary antibodies: MPO (ab208670, Abcam). The sections were then incubated with species-appropriate Alexa Fluor-conjugated IgG (1:500, Invitrogen, USA) for 1 hour at room temperature. Nuclei were counterstained using DAPI before imaging.
Flow cytometry analysis
Mouse neuronal cells isolated from brain tissue were resuspended in binding buffer and dual-labeled with Annexin V-FITC and propidium iodide reagent (Beyotime) for 20 minutes without light. The apoptotic rate was determined by the flow cytometer (Beckman Coulter, Brea, CA, USA). The apoptotic rate is calculated as the sum of cells in Q2 (Upper Right quadrant) and Q3 (Lower Right quadrant), where Q2 represents late apoptotic cells and Q3 represents early apoptotic cells. Three independent replicates were conducted, each using cells isolated from separate mice.
TUNEL staining
To observe apoptotic neurons, TUNEL staining (red) was conducted using a TUNEL kit (Beyotime) according to the manufacturer’s instructions. In brief, neuronal cells on coverslips were fixed with 4% paraformaldehyde for 15 minutes, rinsed three times (3 minutes each) with PBST, then permeabilized with 0.2% Triton X-100 in 1× PBS at room temperature for 5 minutes. After three additional PBS washes, samples were equilibrated with 1× Equilibration Buffer for 15 minutes followed by three PBS rinses. The reaction working solution was applied after buffer removal and incubated at 37°C for 60 minutes. DAPI was added for nuclear counterstaining (5 minutes, protected from light), with excess dye removed by PBS washing. Antifade mounting medium was applied to seal coverslips while avoiding bubble formation. Finally, samples were visualized and representative images captured using fluorescence microscopy (Olympus, Japan).
Cell culture and transfection
BV2 microglial cell line was cultured in a humidified atmosphere with 5% CO2 at 37°C in complete DMEM medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. Upon reaching 70-80% confluence, cells were transfected using Lipofectamine™ 2000 (Invitrogen; Thermo Fisher Scientific, Inc) according to the manufacturer’s instructions. For neutrophils co-culture, culture supernatants of BV2 microglial cell were collected 48 h post-transfection and applied to isolated neutrophils. To investigate the functional role of FKBP5, BV2 cells were divided into four groups: Oe-NC (overexpression control), Oe-FKBP5 (FKBP5 overexpression), si-NC (silencing control) and si-FKBP5 (FKBP5 silencing).
Quantitative real-time polymerase chain reaction
Total RNA was extracted from the cells using Trizol reagent (Invitrogen, Thermo Fisher Scientific), and cDNA was synthesized from 2 μg RNA using the PrimeScript RT Reagent Kit (Takara Bio, Tokyo, Japan) following the manufacturer’s instructions. The PCR assays were performed on a Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA) using SYBR Green PCR Master Mix (Applied Biosystems, Waltham, MA, USA). GAPDH was served as an internal control. mRNA expression was calculated using the comparative 2−ΔΔCt method. The primers used in this study were listed in Table 1.
Table 1
| Gene ID | Primer sequence (5’-3’) |
|---|---|
| FKBP5 | F-CGGCGACAGGTTCTCTACTTA |
| R-CCCTGCCTCTCCAAAACCAT | |
| CCL5 | F-TCATTGCTACTGCCCTCTGC |
| R-TCGGGTGACAAAGACGACTG | |
| GAPDH | F-GCACCGTCAAGGCTGAGAAC |
| R-AGGTGACCGCAGAAGTGGT |
Primer sequence details.
F, Forward; R, Reverse.
Western blot analysis
Protein samples were prepared with an equal volume of loading buffer and denatured at 100°C for 15 minutes. 20 μg of protein in each sample was separated using SDS-PAGE and subsequently transferred to PVDF membranes (Millipore, Temecula, CA, USA). Membranes were blocked with non-specific blocking solution and then incubated overnight at 4°C with primary antibodies: FKBP5 (14155-1-AP, Proteintech), CCL5 (AF5151, Affinity), ERK (BF8004, Affinity), p-ERK (AF1015, Affinity), P38 (14064-1-AP, Proteintech), p-P38 (28796-1-AP, Proteintech), p-JNK (60666-1-Ig, Proteintech), JNK (66210-1-IG, Proteintech), CD206 (60143-1-IG, Proteintech), and GAPDH (60004-1-Ig, Proteintech). After washing in TBST, membranes were incubated with HRP-conjugated secondary antibodies (1:5000, Cell Signaling Technology, USA) at room temperature for 1 hour. GAPDH served as a loading control. Protein bands were visualized using an imaging system (Bio-Rad, Hercules, CA, USA) and quantified using ImageJ software (Version 1.46r, Wayne Rasband, USA). Protein expression levels were quantified by normalizing the grayscale values of target bands to GAPDH loading controls.
Cytokine analysis
Serum levels of IL-1β (ml098416, mlbio), IL-10 (mIC50274-1, mlbio), and TNFα (mIC50536-1, mlbio), iNOS (mlswE3080, mlbio) were determined using ELISA kits (Neobioscience, Beijing, China) according to the manufacturer’s instructions. The absorbance measurements were recorded at 450 nm using a Bio-Tek microplate reader, and the corresponding concentration was converted through the standard curve. The assays were conducted to assess the release of inflammatory cytokines from serum samples.
Neutrophil isolation
Neutrophils were isolated from the circulation using Percoll (GE Healthcare) gradient separation (). First prepare 75% and 62% Percoll solutions. Dilute 5 mL peripheral blood 1:1 with serum-free RPMI 1640. In a 50 mL tube, layer 10 mL 75% Percoll, then carefully add 10 mL 62% Percoll on top. Slowly add 20 mL diluted blood. Centrifuge at 200×g (25 min) then 400×g (15 min) with no brake. Collect neutrophils from the 75%-62% interface, wash with RPMI 1640 (300×g, 5 min), and resuspend in 1 mL neutrophil buffer.
Co-immunoprecipitation
Protein stock was combined with 4× Protein SDS PAGE Loading Buffer, diluted to 1 mg/mL, and denatured at 100°C for 5 minutes to serve as an input control. For Co-IP, 200 μg of protein lysate supernatant was mixed with 2 μg of FKBP5 or CCL5 antibody at 4°C for antigen-antibody binding. A negative control involved using normal rabbit IgG in place of the FKBP5 antibody, following the same incubation period of 24 hours. Dynabeads were pretreated with the lysate in an ice bath three times, at 10-minute intervals, and collected using a magnetic stand. The antigen-antibody mixture was added to the pretreated Dynabeads and incubated for another 2 hours at 4°C with continuous rotation, forming the antigen-FKBP5/CCL5 antibody-Dynabead complex. The beads were magnetically separated, discarding unbound proteins, and mixed with 30 μL of 1× Protein SDS-PAGE loading buffer. The complex was then denatured at 100°C for 5 minutes, with the supernatant collected as the immunoprecipitated protein sample. Finally, western blot analysis was conducted to verify the interactions among FKBP5 and CCL5.
Statistical analysis
GraphPad Prism software version 9.0 was used for data analysis. Data were presented as the mean ± standard deviation. Spearman correlation analysis was used to investigate whether markers of NET formation correlated with ischemic stroke outcomes, with 0.7 ≤ r ≤ 1 termed as strong correlation, 0.4 ≤ r < 0.7 termed as moderate correlation, and 0.2 ≤ r < 0.4 termed as weak correlation (). For comparisons across multiple groups, the one-way analysis of variance (ANOVA) followed by Tukey ‘s honest significant difference test was used. To assess differences between two specific groups, the unpaired t-test was employed. Normality testing was performed for clinical samples, and parametric tests were selected when the data met assumptions of normality and homogeneity of variance. A p-value of less than 0.05 was considered to indicate statistical significance.
Results
Increased expression of FKBP5 and NET in patients with ischemic stroke
Peripheral blood from 40 patients with ischemic stroke and 40 HDs were collected. Clinical characteristics were summarized in Table 2. Patients had a mean age of 62 years, with 18 males (45.0%); comorbid diabetes was present in 42.5% (n=17). Brain tissues were extracted from patients with cerebral infarction and individuals who died in car accidents (each comprising 5 individuals). Transcriptome sequencing data revealed that FKBP5 is significantly upregulated in the patient group, with the log2 fold being changed of 5.405 (p = 1.82E-13), as shown in Supplementary Tables S1, S2. The visualization of sequencing results was shown in Figure 1A. Expanded clinical samples further confirmed the high expression of FKBP5 in stroke patients (Figure 1B). Expression levels of NET-associated markers (H3cit, MPO and dsDNA) were measured in the serum of stroke patients. Our results found that the expression of the NET marker H3cit was significantly increased in ischemic stroke patients within 24 hours compared to HDs (Figure 1C). ELISA analysis demonstrated a marked elevation in the total content of the MPO-DNA complex in plasma samples from stroke patients compared to those from HD (Figure 1D). Additionally, plasma DNA levels were significantly increased in stroke patients in comparison to the HDs (Figure 1E). The results indicated the elevated NET formation in the peripheral blood of stroke patients compared to those of HD. We next used a Spearman correlation analysis to investigate whether markers of NET formation correlated with ischemic stroke outcomes. As shown in Table 3, both plasma H3cit and MPO-DNA levels positively correlated with stroke severity (r = 0.332, P = 0.036 and r = 0.391, P = 0.013, respectively) and stroke outcomes (r = 0.379, P = 0.016 and r = 0.466, P = 0.002, respectively), implying the positive correlation between NET formation and stroke severity.
Table 2
| Characteristics | Healthy donors (n=40) | Ischemic stroke (n=40) | P-value |
|---|---|---|---|
| Age (mean ± SD; years) | 57 ± 15 | 62 ± 14 | 0.1273 |
| Female (%) | 40% | 45% | 0.7979 |
| Diabetes (%) | 8% | 42.50% | 0.0003 |
| Hyperlipidemia (%) | 5.00% | 22.50% | 0.0239 |
| Hypertension (%) | 12.50% | 57.50% | <0.0001 |
| Hyperhomocysteinemia (%) | 5% | 38% | 0.0004 |
| Stroke Severity (median(range); NIHSS at admission) | 5 (0-15) | ||
| Stroke Outcome (median(range); mRS at discharge) | 2 (0-5) | ||
| TOAST subtype | |||
| LAA | 11 | NA | |
| CE | 6 | NA | |
| SVD | 12 | NA | |
| Other | 5 | NA | |
| Unknown | 6 | NA | |
| Medication | |||
| Anti-coagulation | 13 | NA | |
| Anti-platelets | 16 | NA | |
| Thrombolysis | 11 | NA | |
Clinical characteristics of the stroke patients and healthy donors.
SD, Standard deviation; NIHSS, National Institutes of Health Stroke Scale; TOAST, Trial of Org 10172 in Acute Stroke Treatment; LAA, Large artery atherosclerosis; CE, Cardioembolic; SVD, Small vessel disease.
Figure 1
Table 3
| NET markers | Stroke severity | Stroke outcome |
|---|---|---|
| H3cit | r = 0.3322; p = 0.0362 | r = 0.3788; p =0.0159 |
| MPO-DNA | r = 0.3908; p = 0.0127 | r = 0.4663; p = 0.0024 |
| dsDNA | r = -0.03796; p = 0.8161 | r = -0.1895; p = 0.2416 |
Correlations between NET markers, stroke severity and stroke outcome.
Inhibition of NETs attenuates brain injury in tMCAO model
We then intended to demonstrate if the administration of the NETs inhibitor leads to the improvement of stroke-related brain injury in tMCAO mice, as well as changes in NETs-related indicators. Mice were randomly divided into three groups: sham group, tMCAO model (stroke) and tMCAO+CI-amidine (stroke+CI). Our results demonstrated that the administration of the NETs inhibitor significantly reduced the infarct area and water content, a factor that constitutes a cardinal pathological process that severely compromises prognosis following ischemic stroke, in the brains of mice subjected to stroke by TTC staining and BWC analysis (Figures 2A–C), demonstrating the relieving effect of NET inhibition on stroke. Plasma levels of H3cit and MPO-DNA complexes were increased 24 hours post-stroke induction and decreased following the treatment of NETs inhibitor (Figures 2D, E). Histological examination of the peri-infarct cortex using HE staining revealed a reduction in neuronal damage following NETs inhibitor treatment (Figure 2F), further indicated the relieving effect of NET inhibition on stroke. Immunohistochemical analysis showed a higher positive expression for H3cit and MPO in the stroke group compared to the sham group, while the positive expression was decreased in the stroke+CI group (Figures 2G, H). Finally, immunofluorescence staining showed a higher positivity rate for Ly6G (neutrophil marker) and MPO in the stroke group compared to the sham group, while the positivity rate was decreased in the stroke+CI group (Figures 2I, J). These results further confirmed the elevated NET formation in stroke.
Figure 2
Effects of NET inhibitor on neuronal apoptosis
Based on the results of histological examination, we further evaluated the effects of NET inhibitor on neuronal apoptosis. Primary neurons were isolated from mouse brain tissue. Flow cytometry and TUNEL assays were used to evaluate the effect of NETs inhibitors on neuronal apoptosis. Compared to the sham group, the stroke group exhibited significantly increased levels of neuronal apoptosis, which were reduced after NETs inhibitor treatment (Figures 3A, B). The TUNEL assay produced consistent results, showing that the number of apoptotic cells in the stroke group was higher compared to the sham group, while the administration of the inhibitor resulted in a decrease in the number of apoptotic cells (Figure 3C).
Figure 3
Effects of FKBP5 expression on microglial polarization and NET formation
To investigate the function of FKBP5 in microglial polarization, primary microglia were isolated from brain tissue, and qPCR and Western blotting analyses were conducted to assess FKBP5 expression levels. The results showed that FKBP5 level was significantly elevated in the stroke group compared to the sham group, and the expression significantly decreased in the stroke+CI group (Figures 4A–C). Furthermore, BV2 microglial cells were transfected with FKBP5 overexpression and knockdown vectors, showing that FKBP5 overexpression promoted M1 polarization, evidenced by elevated expression of M1 markers TNFα, IL-1β and iNOS (Figures 4D–F). In contrast, the expression of M2 markers IL-10 and CD206 decreased when FKBP5 was overexpressed (Figures 4G–I). Co-culture of BV2 cells with neutrophils from peripheral blood of patients revealed that FKBP5 overexpression significantly increased MPO-DNA and H3cit levels, promoting NET formation, while NET inhibitor treatment decreased the levels of MPO-DNA and H3cit (Figures 4J, K). Collectively, these results suggested that FKBP5 facilitates M1 polarization of microglia and promotes the formation of NETs.
Figure 4
Interaction between FKBP5 and CCL5
One recent study indicated that the level of CCL5 may be predictive of infarct volume outcomes in patients with ischemic stroke (). To explore the potential interaction between FKBP5 and CCL5, we conducted the molecular simulation docking visualization analysis using human proteins (Figures 5A). The rigid docking between these proteins yielded a calculated free energy of −8.2 kcal/mol (a negative binding energy value), which implies a structural foundation for spontaneous docking between two predicted protein models. Moreover, subcellular localization analysis suggested a potential overlap during the entirety of cellular development (Figures 5B). To further investigate the molecular association between FKBP5 and CCL5, the Co-IP assay was performed (Figures 5C) and our results confirmed that CCL5 and FKBP5 can bind to one another within total protein extracts. Further analysis via qPCR and Western blotting confirmed that FKBP5 promotes the expression of CCL5 following transfection of overexpression and interference vectors of FKBP5 into BV2 cells (Figures 5D–G). These results revealed the regulatory effect of FKBP5 on CCL5.
Figure 5
FKBP5 activates the MAPK signaling pathway via CCL5
Pathway enrichment analysis of differentially expressed gene between ischemic stroke patients and HDs revealed that the MAPK signaling pathway may play an important role in stroke (Supplementary Table S3). Further validation experiment demonstrated that the overexpression of FKBP5 can activate the MAPK signaling pathway, leading to enhanced expression levels of p-p38, p-JNK and p-ERK. When BV2 cells were co-transfected with the FKBP5 overexpression vector (Oe-FKBP5) and CCL5 interference vector (si-CCL5), it was observed that the promoting effect of FKBP5 on the MAPK signaling pathway could be inhibited by si-CCL5 (Figure 6A). The grayscale analysis of the proteins supported these findings (Figures 6B–D).
Figure 6
The effect of FKBP5-CCL5 on BV2 cell polarization and neutrophil NETs formation via the MAPK signaling pathway
Previous studies have identified the impact of MAPK signaling pathway on NETs formation and cell polarization (, ). Based on the above findings, we hypothesize that FKBP5-CCL5 -mediated regulation of microglial polarization and NET formation may be associated with the MAPK signaling pathway. ELISA assays revealed that the levels of pro-inflammatory cytokines TNFα and IL-1β are significantly increased following the overexpression of FKBP5 (Figures 7A, B). Treatment with the MAPK pathway inhibitor AZD6244 (10 μM) or si-CCL5 led to a marked reduction in the expression of TNFα and IL-1β (Figures 7A, B). Additionally, when BV2 cells overexpressing FKBP5 were co-cultured with neutrophils following AZD6244 treatment or si-CCL5, it was observed that AZD6244 or si-CCL5 effectively inhibited the increase of NET markers (MPO-DNA and H3cit) induced by FKBP5 (Figures 7C, D). Overall, these results confirmed the involvement of the MAPK pathway in mediating the effects of FKBP5-CCL5.
Figure 7
Discussion
This work validated our hypothesis that FKBP5 might mediate ischemic stroke through regulating NETs and microglia polarization. The current findings demonstrate that FKBP5, through its interaction with CCL5, activates the p38 MAPK signaling pathway in BV2 cells. This activation promotes the differentiation of BV2 cells into M1 macrophages, resulting in the release of pro-inflammatory factors such as IL-1β and TNF-α. In addition, this signaling cascade enhances the formation of NETs, which contributes to subsequent neurodegeneration and the apoptosis of neuronal cells.
NETs - lattices of extracellular DNA released by neutrophils - function to entrap and eliminate pathogens (). In the bloodstream, NETs promote thrombus formation to restrict dissemination of infectious agents (). However, excessive NET generation exacerbates cardiovascular pathology through clot stabilization (), microvascular thrombosis induction (), and endothelial cell death (). Multiple studies have identified NETs within thrombi from ischemic stroke patients, where they confer resistance to tissue-type plasminogen activator (, , ). Herein, we demonstrate the presence of NETs in patients with ischemic stroke, as demonstrated by the upregulation of NET formation markers (H3cit, MPO, and dsDNA). This was further observed in tMCAO stroke model mice, and NET inhibition suppressed neurons apoptosis isolated from tMCAO stroke model mice. Similar to previous study (), these findings established NET formation as a clinically significant pathogenic mechanism in ischemic stroke. Further in vitro experiments demonstrated the promotion impact of FKBP5 on NET formation, indicating the potential function of FKBP5 in stroke through regulation NET.
The current findings also suggested that FKBP5 overexpression promoted microglia M1 polarization, evidenced by elevated expression of M1 markers TNFα, IL-1β and iNOS, and inhibited M1 polarization, evidenced by attenuated expression of M2 markers IL-10 and CD206 (). Microglia, the resident immune cells of the central nervous system, are established mediators of neuroinflammation in ischemic stroke (, ). Following activation, these cells undergo polarization into pro-inflammatory (M1) or anti-inflammatory (M2) phenotypes, exerting dual-and often opposing-effects on post-ischemic brain injury, repair, and regeneration (). M1-polarized microglia release proinflammatory cytokines (e.g., TNFα, IL-1β) and chemokines that amplify neuroimmune responses and exacerbate neuronal damage. Conversely, M2 microglia promote tissue repair through secretion of anti-inflammatory mediators (e.g., IL-10, TGF-β) that resolve inflammation and support neurorestorative processes (, ). Collectively, this study indicated that FKBP5 might mediate ischemic stroke through regulating microglia polarization. In addition, the release of these pro-inflammatory cytokines, such as IL-1β and TNFα, is instrumental in enhancing the formation of NETs. The increased presence of NETs promotes neuroinflammation and contributes to the formation of thrombi, which can obstruct cerebral blood flow and worsen ischemic conditions (). The subsequent neurodegeneration and apoptosis of neuronal cells can be attributed to sustained inflammatory environment fostered by NETs and the activated p38 MAPK pathway (). This is significant because the continuous cycle of inflammation and cell damage leads to detrimental outcomes in stroke patients, emphasizing the need for therapeutic approaches that can disrupt this cycle. Given the dual role of NETs in promoting thrombosis and neuroinflammation, targeting NET formation (CI-amidine utilization) or promoting their clearance represents a promising therapeutic strategy.
The interplay between FKBP5 and CCL5 is particularly noteworthy, as CCL5 is a chemokine that attracts immune cells to sites of injury (). The interaction between FKBP5 and CCL5 further underscores the role of FKBP5 in mediating inflammatory signals within the central nervous system. We propose that FKBP5 not only initiates the inflammatory cascade but also serves to amplify it, consequently leading to the promotion of neuronal cell apoptosis and neurodegeneration. As transcriptome sequencing predicated the important function of MAPK pathway in stroke, and previous study has reported that CCL5 can directly initiate M1 polarization and inhibit M2 polarization through the activation of the MAPK pathway via CCR1 and CCR5 receptors (). Thus, we therefore prioritized analysis of the MAPK signaling cascade based on preliminary evidence. Intriguingly, FKBP5 exhibited MAPK pathway-activating functionality, which was suppressed upon CCL5 inhibition co-treatment. MAPKs are a crucial family of proteins that play significant roles in various cellular responses, including cellular proliferation, differentiation and apoptosis (). The activation of p38 MAPK leads to neuronal apoptosis, blood-brain barrier disruption and inflammatory responses, serving as critical contributors to secondary injury following stroke (, ). Specific p38 MAPK inhibitors may reduce ischemic brain injury and improve neurological recovery in animal models (). Blocking p38 MAPK can attenuate the activation of microglia following stroke, thereby reducing the release of inflammatory cytokines (). This is crucial in preventing the exacerbation of brain damage due to secondary inflammatory responses, implying the therapeutic potential of MAPK inhibitors such as AZD6244 in ischemic stroke.
There are several limitations of this study. A key methodological limitation concerns our approach to verifying the tMCAO model. While neurological function scoring was systematically applied to assess ischemic deficits, we did not employ laser Doppler flowmetry to objectively blood flow reduction during MCA occlusion. The absence of real-time hemodynamic confirmation introduces potential uncertainty regarding the consistency and completeness of vascular occlusion across subjects. Another limitation of this study is that RNA-seq was performed with only five subjects per group, which constrains the statistical power. To mitigate this issue and strengthen our conclusions, future prospective validation studies will incorporate larger sample sizes. In addition, our current findings are exclusively derived from in vitro cellular models examining FKBP5’s mechanistic role in ischemic stroke, necessitating further validation through the development of FKBP5-knockdown mouse models to substantiate these conclusions. For future research, we will increase biological replicates and incorporate prospective power analysis to optimize sample size determination.
Conclusion
FKBP5 and CCL5 modulate p38 MAPK signaling and NET formation, contributing to post-stroke neuroinflammation and neuronal apoptosis. Further prospective research and in vivo experiments using FKBP5 knockout models are needed to investigate the potential of FKBP5 as therapeutic targets for ischemic stroke treatment.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.
Ethics statement
The study received approval from the ethics committee of Liaocheng People’s Hospital and adhered to the principles of the Declaration of Helsinki. Informed consent was obtained from all participants, and written consent was specifically obtained from the parents of participants. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by the Ethics Committee for Experimental Animals of Liaocheng People’s Hospital. The study was conducted in accordance with the local legislation and institutional requirements.
Author contributions
ZcL: Conceptualization, Writing – original draft. TY: Conceptualization, Writing – original draft. HG: Writing – original draft, Data curation. ZxL: Data curation, Writing – original draft. PW: Writing – original draft, Data curation. CL: Formal analysis, Writing – original draft. QW: Formal analysis, Writing – original draft. MZ: Writing – original draft, Formal analysis. YX: Writing – original draft, Data curation. JW: Writing – review & editing. JH: Writing – review & editing. LZ: Writing – review & editing.
Funding
The author(s) declare financial support was received for the research and/or publication of this article. This work was supported by Natural Science Foundation of Shandong Province (grant number ZR2022QH125); Medical and Health Science and Technology Development Plan of Shandong Province (grant number 202104090566); Project of Medical Staff Science and Technology Innovation Plan of Shandong Province (grant number SDYWZGKCJH2023021); Project supported by the National Natural Science Foundation of China (Grant No. 82401537).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Correction note
A correction has been made to this article. Details can be found at: 10.3389/fimmu.2025.1744810.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1609989/full#supplementary-material
References
1
FeiginVLForouzanfarMHKrishnamurthiRMensahGAConnorMBennettDAet al. Global and regional burden of stroke during 1990-2010: Findings from the global burden of disease study 2010. Lancet (London England). (2014) 383:245–54. doi: 10.1016/S0140-6736(13)61953-4
2
OhashiSNDeLongJHKozbergMGMazur-HartDJvan VeluwSJAlkayedNJet al. Role of inflammatory processes in hemorrhagic stroke. Stroke. (2023) 54:605–19. doi: 10.1161/STROKEAHA.122.037155
3
IadecolaCBuckwalterMSAnratherJ. Immune responses to stroke: Mechanisms, modulation, and therapeutic potential. J Clin Invest. (2020) 130:2777–88. doi: 10.1172/JCI135530
4
WangRZhuYLiuZChangLBaiXKangLet al. Neutrophil extracellular traps promote tpa-induced brain hemorrhage via cgas in mice with stroke. Blood. (2021) 138:91–103. doi: 10.1182/blood.2020008913
5
GaoXZhaoXLiJLiuCLiWZhaoJet al. Neutrophil extracellular traps mediated by platelet microvesicles promote thrombosis and brain injury in acute ischemic stroke. Cell Commun Signaling: CCS. (2024) 22:50. doi: 10.1186/s12964-023-01379-8
6
LiPLiMLindbergMRKennettMJXiongNWangY. Pad4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J Exp Med. (2010) 207:1853–62. doi: 10.1084/jem.20100239
7
ThalinCDaleskogMGoranssonSPSchatzbergDLasselinJLaskaACet al. Validation of an enzyme-linked immunosorbent assay for the quantification of citrullinated histone h3 as a marker for neutrophil extracellular traps in human plasma. Immunol Res. (2017) 65:706–12. doi: 10.1007/s12026-017-8905-3
8
YazdaniHORoyEComerciAJvan der WindtDJZhangHHuangHet al. Neutrophil extracellular traps drive mitochondrial homeostasis in tumors to augment growth. Cancer Res. (2019) 79:5626–39. doi: 10.1158/0008-5472.CAN-19-0800
9
ZhangDGuoJShiCWangYZhangYZhangXet al. Mpo-DNA complexes and cf-DNA in patients with sepsis and their clinical value. Biomedicines. (2024) 12:2190. doi: 10.3390/biomedicines12102190
10
LuoHGuoHZhouYFangRZhangWMeiZ. Neutrophil extracellular traps in cerebral ischemia/reperfusion injury: Friend and foe. Curr Neuropharmacol. (2023) 21:2079–96. doi: 10.2174/1570159X21666230308090351
11
ZhouJGuoPHaoXSunXFengHChenZ. Neutrophil extracellular traps (nets): A new therapeutic target for neuroinflammation and microthrombosis after subarachnoid hemorrhage? Trans Stroke Res. (2023) 14:443–5. doi: 10.1007/s12975-022-01039-y
12
LanXHanXLiQYangQWWangJ. Modulators of microglial activation and polarization after intracerebral haemorrhage. Nat Rev Neurol. (2017) 13:420–33. doi: 10.1038/nrneurol.2017.69
13
HuXLeakRKShiYSuenagaJGaoYZhengPet al. Microglial and macrophage polarization—new prospects for brain repair. Nat Rev Neurol. (2015) 11:56–64. doi: 10.1038/nrneurol.2014.207
14
Criado-MarreroMReinTBinderEBPorterJTKorenJBlairLJ. Hsp90 and fkbp51: Complex regulators of psychiatric diseases. Philos Trans R Soc London Ser B Biol Sci. (2018) 373:20160532. doi: 10.1098/rstb.2016.0532
15
ZannasASJiaMHafnerKBaumertJWiechmannTPapeJCet al. Epigenetic upregulation of fkbp5 by aging and stress contributes to nf-κb-driven inflammation and cardiovascular risk. Proc Natl Acad Sci United States Am. (2019) 116:11370–9. doi: 10.1073/pnas.1816847116
16
YuSYuMBuZHePFengJ. Fkbp5 exacerbates impairments in cerebral ischemic stroke by inducing autophagy via the akt/foxo3 pathway. Front Cell Neurosci. (2020) 14:193. doi: 10.3389/fncel.2020.00193
17
FangYNiuXZhaoWZhangH. Cardioprotective potential of transcription factor prrx1 silencing against myocardial ischemia/reperfusion injury by regulating excessive mitophagy and ferroptosis through fkbp5-p38 mapk axis. Biochim Biophys Acta Mol Basis Dis. (2025) 1871:167766. doi: 10.1016/j.bbadis.2025.167766
18
SongQSongCChenXXiongYLiLLiaoWet al. Fkbp5 deficiency attenuates calcium oxalate kidney stone formation by suppressing cell-crystal adhesion, apoptosis and macrophage m1 polarization via inhibition of nf-κb signaling. Cell Mol Life Sci: CMLS. (2023) 80:301. doi: 10.1007/s00018-023-04958-7
19
CaiWWangJHuMChenXLuZBellantiJAet al. All trans-retinoic acid protects against acute ischemic stroke by modulating neutrophil functions through stat1 signaling. J Neuroinflamm. (2019) 16:175. doi: 10.1186/s12974-019-1557-6
20
WangCYLinTTHuLXuCJHuFWanLet al. Neutrophil extracellular traps as a unique target in the treatment of chemotherapy-induced peripheral neuropathy. EBioMedicine. (2023) 90:104499. doi: 10.1016/j.ebiom.2023.104499
21
QuXHouXZhuKChenWChenKSangXet al. Neutrophil extracellular traps facilitate sympathetic hyperactivity by polarizing microglia toward m1 phenotype after traumatic brain injury. FASEB J. (2023) 37:e23112. doi: 10.1096/fj.202300752R
22
ZannasASBinderEB. Gene-environment interactions at the fkbp5 locus: Sensitive periods, mechanisms and pleiotropism. Genes Brain Behav. (2014) 13:25–37. doi: 10.1111/gbb.12104
23
LiTYueYMaYZhongZGuoMZhangJet al. Fasting-mimicking diet alleviates inflammatory pain by inhibiting neutrophil extracellular traps formation and neuroinflammation in the spinal cord. Cell Commun Signal. (2023) 21:250. doi: 10.1186/s12964-023-01258-2
24
MamtilahunMTangGZhangZWangYTangYYangGY. Targeting water in the brain: Role of aquaporin-4 in ischemic brain edema. Curr Drug Targets. (2019) 20:748–55. doi: 10.2174/1389450120666190214115309
25
XieJZhangTLiPWangDLiuTXuS. Dihydromyricetin attenuates cerebral ischemia reperfusion injury by inhibiting sphk1/mtor signaling and targeting ferroptosis. Drug Des Devel Ther. (2022) 16:3071–85. doi: 10.2147/DDDT.S378786
26
ZhangPYouSDingXLuanPXuJCuiQet al. Protective effect and underlying mechanism of muscone on acute cerebral ischemia-reperfusion injury in rats. J Ethnopharmacol. (2023) 308:116287. doi: 10.1016/j.jep.2023.116287
27
LiaoYChengJKongXLiSLiXZhangMet al. Hdac3 inhibition ameliorates ischemia/reperfusion-induced brain injury by regulating the microglial cgas-sting pathway. Theranostics. (2020) 10:9644–62. doi: 10.7150/thno.47651
28
MuradMLowLDavidsonMMurrayPIRauzSWallaceGR. Low density neutrophils are increased in patients with behcet’s disease but do not explain differences in neutrophil function. J Inflammation (Lond). (2022) 19:5. doi: 10.1186/s12950-022-00302-1
29
ZarJ. H. Biostatistical analysis. 5th ed. Pearson Prentice-Hall (2014).
30
Julián-VillaverdeFJSerrano-PonzMRamalle-GómaraEMartínezAOchoa-CallejeroL. Ccl5 levels predict stroke volume growth in acute ischemic stroke and significantly diminish in hemorrhagic stroke patients. Int J Mol Sci. (2022) 23:9967. doi: 10.3390/ijms23179967
31
ChenXSWangSHLiuCYGaoYLMengXLWeiWet al. Losartan attenuates sepsis-induced cardiomyopathy by regulating macrophage polarization via tlr4-mediated nf-kappab and mapk signaling. Pharmacol Res. (2022) 185:106473. doi: 10.1016/j.phrs.2022.106473
32
LiJXiaYSunBZhengNLiYPangXet al. Neutrophil extracellular traps induced by the hypoxic microenvironment in gastric cancer augment tumour growth. Cell Commun Signal. (2023) 21:86. doi: 10.1186/s12964-023-01112-5
33
SorvilloNCherpokovaDMartinodKWagnerDD. Extracellular DNA net-works with dire consequences for health. Circ Res. (2019) 125:470–88. doi: 10.1161/CIRCRESAHA.119.314581
34
MassbergSGrahlLvon BruehlMLManukyanDPfeilerSGoosmannCet al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med. (2010) 16:887–96. doi: 10.1038/nm.2184
35
LaridanEDenormeFDesenderLFrancoisOAnderssonTDeckmynHet al. Neutrophil extracellular traps in ischemic stroke thrombi. Ann Neurol. (2017) 82:223–32. doi: 10.1002/ana.24993
36
MangoldAOndracekASHofbauerTMScherzTArtnerTPanagiotidesNet al. Culprit site extracellular DNA and microvascular obstruction in st-elevation myocardial infarction. Cardiovasc Res. (2022) 118:2006–17. doi: 10.1093/cvr/cvab217
37
FranckGMawsonTLFolcoEJMolinaroRRuvkunVEngelbertsenDet al. Roles of pad4 and netosis in experimental atherosclerosis and arterial injury: Implications for superficial erosion. Circ Res. (2018) 123:33–42. doi: 10.1161/CIRCRESAHA.117.312494
38
DucrouxCDi MeglioLLoyauSDelboscSBoisseauWDeschildreCet al. Thrombus neutrophil extracellular traps content impair tpa-induced thrombolysis in acute ischemic stroke. Stroke. (2018) 49:754–7. doi: 10.1161/STROKEAHA.117.019896
39
NovotnyJOberdieckPTitovaAPelisekJChandraratneSNicolPet al. Thrombus net content is associated with clinical outcome in stroke and myocardial infarction. Neurology. (2020) 94:e2346–60. doi: 10.1212/WNL.0000000000009532
40
DenormeFPortierIRustadJLCodyMJde AraujoCVHokiCet al. Neutrophil extracellular traps regulate ischemic stroke brain injury. J Clin Invest. (2022) 132:e154225. doi: 10.1172/JCI154225
41
AttaAAIbrahimWWMohamedAFAbdelkaderNF. Microglia polarization in nociplastic pain: Mechanisms and perspectives. Inflammopharmacology. (2023) 31:1053–67. doi: 10.1007/s10787-023-01216-x
42
XiongXYLiuLYangQW. Functions and mechanisms of microglia/macrophages in neuroinflammation and neurogenesis after stroke. Prog Neurobiol. (2016) 142:23–44. doi: 10.1016/j.pneurobio.2016.05.001
43
BenarrochEE. Microglia: Multiple roles in surveillance, circuit shaping, and response to injury. Neurology. (2013) 81:1079–88. doi: 10.1212/WNL.0b013e3182a4a577
44
HuXLiPGuoYWangHLeakRKChenSet al. Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke. (2012) 43:3063–70. doi: 10.1161/STROKEAHA.112.659656
45
HouKXiaoZCDaiHL. P38 mapk endogenous inhibition improves neurological deficits in global cerebral ischemia/reperfusion mice. Neural Plasticity. (2022) 2022:3300327. doi: 10.1155/2022/3300327
46
ZengZLanTWeiYWeiX. Ccl5/ccr5 axis in human diseases and related treatments. Genes Dis. (2022) 9:12–27. doi: 10.1016/j.gendis.2021.08.004
47
LiMSunXZhaoJXiaLLiJXuMet al. Ccl5 deficiency promotes liver repair by improving inflammation resolution and liver regeneration through m2 macrophage polarization. Cell Mol Immunol. (2020) 17:753–64. doi: 10.1038/s41423-019-0279-0
48
KimEKChoiEJ. Pathological roles of mapk signaling pathways in human diseases. Biochim Biophys Acta. (2010) 1802:396–405. doi: 10.1016/j.bbadis.2009.12.009
49
YongHYKohMSMoonA. The p38 mapk inhibitors for the treatment of inflammatory diseases and cancer. Expert Opin Investigat Drugs. (2009) 18:1893–905. doi: 10.1517/13543780903321490
50
KumarSBoehmJLeeJC. P38 map kinases: Key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov. (2003) 2:717–26. doi: 10.1038/nrd1177
51
BaroneFCParsonsAA. Therapeutic potential of anti-inflammatory drugs in focal stroke. Expert Opin Investigat Drugs. (2000) 9:2281–306. doi: 10.1517/13543784.9.10.2281
52
ZengJBaoTYangKZhuXWangSXiangWet al. The mechanism of microglia-mediated immune inflammation in ischemic stroke and the role of natural botanical components in regulating microglia: A review. Front Immunol. (2022) 13:1047550. doi: 10.3389/fimmu.2022.1047550
Summary
Keywords
ischemic stroke, FKBP5, CCL5, NET, MAPK
Citation
Li Z, Yin T, Guo H, Liu Z, Wang P, Liu C, Wang Q, Zhang M, Xiao Y, Wang J, Hao J and Zhang L (2025) FKBP5-CCL5 interaction promotes neuroinflammation and neuronal apoptosis in ischemic stroke by regulating the MAPK pathway and enhancing NET formation. Front. Immunol. 16:1609989. doi: 10.3389/fimmu.2025.1609989
Received
11 April 2025
Accepted
11 September 2025
Published
30 September 2025
Corrected
19 December 2025
Volume
16 - 2025
Edited by
Yaping Yan, Shaanxi Normal University, China
Reviewed by
Mustafa Caglar Beker, Istanbul Medeniyet University, Türkiye
Carolina Pena Martinez, Faculty of Health Sciences. Universidad Rey Juan Carlos, Spain
Updates
Copyright
© 2025 Li, Yin, Guo, Liu, Wang, Liu, Wang, Zhang, Xiao, Wang, Hao and Zhang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jiheng Hao, haojiheng@163.com; Liyong Zhang, 13346256936@163.com; Jiyue Wang, jiyuewang@163.com
These authors share first authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.